S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
S&P 500   4,023.89
DOW   32,196.66
QQQ   301.94
NYSE:VOR

Vor Biopharma News Headlines

$4.22
-0.18 (-4.09%)
(As of 05/13/2022 04:00 PM ET)
Add
Compare
Today's Range
$4.13
$4.58
50-Day Range
$4.22
$8.65
52-Week Range
$4.13
$23.96
Volume
85,189 shs
Average Volume
105,920 shs
Market Capitalization
$158.29 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
-0.38
Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.

Media Mentions By Week

Vor Biopharma Media Sentiment

Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press.

VOR
News Sentiment

-0.02

0.48

Average
Medical
News Sentiment

Media Coverage

We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week.

VOR Articles
This Week

4

1

VOR Articles
Average Week



Vor Biopharma (NYSE:VOR) News Headlines Today

SourceHeadline
marketbeat.com logoVor Biopharma Inc. (NYSE:VOR) Given Consensus Rating of "Buy" by Analysts
marketbeat.com - May 15 at 8:45 AM
marketbeat.com logoJMP Securities Cuts Vor Biopharma (NYSE:VOR) Price Target to $15.00
marketbeat.com - May 13 at 12:23 PM
markets.businessinsider.com logoExpert Ratings for Vor Biopharma
markets.businessinsider.com - May 13 at 1:31 PM
finance.yahoo.com logoWe Think Vor Biopharma (NASDAQ:VOR) Can Afford To Drive Business Growth
finance.yahoo.com - May 7 at 1:12 PM
finanznachrichten.de logoKedrion Biopharma tilgt 200 Millionen Euro seiner 2022 fälligen Anleihen
finanznachrichten.de - May 2 at 8:14 AM
seekingalpha.com logoVor Biopharma initiated at neutral at Goldman as value proposition yet to be determined
seekingalpha.com - April 27 at 1:07 PM
msn.com logoWas hat Elon Musk mit Twitter vor? - Viele offene Fragen nach Übernahme
msn.com - April 26 at 2:56 PM
finance.yahoo.com logoVor Bio Announces Retirement of Chief Medical Officer
finance.yahoo.com - April 14 at 8:45 PM
finance.yahoo.com logoAkron BioProducts and Vor Bio to Collaborate on the Development and cGMP Manufacture of Nucleases
finance.yahoo.com - March 22 at 4:15 PM
benzinga.com logoBarclays Maintains Overweight on Vor Biopharma, Lowers Price Target to $26
benzinga.com - March 21 at 9:30 AM
seekingalpha.com logoVor Bioipharma files for $350M mixed shelf offering
seekingalpha.com - March 14 at 10:53 PM
finance.yahoo.com logoVor Bio Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Company Update
finance.yahoo.com - March 14 at 5:52 PM
de.finance.yahoo.com logoAlvotech und Fuji Pharma erweitern ihre Zusammenarbeit um zusätzlichen Biosimilar-Kandidaten in Japan
de.finance.yahoo.com - February 24 at 7:41 AM
finance.yahoo.com logoVor to Participate in the 11th Annual SVB Leerink Global Healthcare Conference
finance.yahoo.com - February 11 at 9:08 AM
nasdaq.com logoVor Biopharma Inc. Common Stock (VOR)
nasdaq.com - January 20 at 8:02 PM
nasdaq.com logoVor Biopharma Inc Shares Approach 52-Week Low - Market Mover
nasdaq.com - January 8 at 9:41 AM
benzinga.com logoVor Biopharma shares are trading higher after HC Wainwright initiated coverage on the stock with a Buy rating and $26 price target.
benzinga.com - December 17 at 3:08 PM
finance.yahoo.com logoVor to Participate in the JMP Securities Hematology and Oncology Summit
finance.yahoo.com - November 29 at 10:32 AM
benzinga.com logoVor Biopharma Insider Sold Over $5.0M In Company Stock
benzinga.com - November 19 at 1:33 PM
finance.yahoo.com logoDoes Vor Biopharma (VOR) Have the Potential to Rally 186% as Wall Street Analysts Expect?
finance.yahoo.com - November 15 at 3:02 PM
finance.yahoo.com logoWe're Hopeful That Vor Biopharma (NASDAQ:VOR) Will Use Its Cash Wisely
finance.yahoo.com - November 11 at 3:45 PM
finance.yahoo.com logoVor Reports Third Quarter 2021 Financial Results and Provides Company Update
finance.yahoo.com - November 10 at 7:02 PM
finance.yahoo.com logoVor to Present New Data on its Cell and Genome Engineering Platform at SITC Annual Meeting
finance.yahoo.com - November 9 at 8:48 AM
finance.yahoo.com logoVor to Participate in Two Upcoming Investor Conferences
finance.yahoo.com - November 8 at 8:31 AM
finance.yahoo.com logoVor to Present New Platform and Preclinical Data at ASH
finance.yahoo.com - November 4 at 9:27 AM
finance.yahoo.com logoVor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT
finance.yahoo.com - October 19 at 7:35 AM
finance.yahoo.com logoVor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management
finance.yahoo.com - October 12 at 9:13 AM
finance.yahoo.com logoEnara Bio announces the appointment of highly experienced biotech executive Dr. Robert Ang to its Board of Directors
finance.yahoo.com - September 28 at 7:30 AM
nasdaq.com logoVor Biopharma Says FDA Grants Fast Track Designation To VOR33 For Acute Myeloid Leukemia
nasdaq.com - September 10 at 3:35 AM
markets.businessinsider.com logoVor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US
markets.businessinsider.com - September 9 at 12:31 PM
finance.yahoo.com logoVOR33 Granted U.S. FDA Fast Track Designation for AML
finance.yahoo.com - September 9 at 12:31 PM
finance.yahoo.com logoVor to Participate in Three Upcoming Investor Conferences
finance.yahoo.com - September 2 at 8:59 AM
markets.businessinsider.com logoCresa Boston Assists Vor Biopharma to Expand Its Footprint and Create In-house Clinical Manufacturing Facility
markets.businessinsider.com - August 24 at 4:40 PM
barrons.com logoVor Biopharma Inc.
barrons.com - August 20 at 5:53 PM
finance.yahoo.com logoVor Reports Second Quarter 2021 Financial Results and Provides Company Update
finance.yahoo.com - August 9 at 6:13 PM
msn.com logoBRIEF-Puretech Founded Entity Vor Biopharma Announces Collaboration With Janssen To Develop Engineered Hematopoietic Stem Cell Transplants Combined With A Bi-Specific Antibody ...
msn.com - July 9 at 9:41 AM
marketwatch.com logoVor Biopharma Working With Janssen Biotech on Leukemia Treatment
marketwatch.com - July 9 at 9:41 AM
markets.businessinsider.com logoVor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia
markets.businessinsider.com - July 8 at 1:38 PM
bizjournals.com logoThe Petri Dish: Moderna launches flu trial, Vor teams with Janssen
bizjournals.com - July 8 at 8:38 AM
msn.com logoBRIEF-Vor Biopharma Announces Collaboration With Janssen To Develop Treatment For Acute Myeloid Leukemia (Aml)
msn.com - July 8 at 8:38 AM
finance.yahoo.com logoVor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined With a Bi-Specific Antibody Therapy for Acute Myeloid Leukemia (AML)
finance.yahoo.com - July 8 at 8:38 AM
finance.yahoo.com logoVor to Build-Out State-of-the-Art Clinical Manufacturing Facility Capable of Supporting Multiple Cell Therapy Programs
finance.yahoo.com - June 17 at 8:18 AM
marketwatch.com logoVor Biopharma Names Matthew Patterson Board Chair
marketwatch.com - June 11 at 9:21 AM
marketwatch.com logoVor Biopharma Shares Rise 9% on License Agreement With Abound Bio
marketwatch.com - June 10 at 6:38 PM
marketwatch.com logoVor Biopharma, Abound Bio in Licensing Agreement for Leukemia Treatment
marketwatch.com - June 10 at 1:37 PM
finance.yahoo.com logoVor to Develop Multi-Targeted CAR-Ts with Abound Bio
finance.yahoo.com - June 10 at 8:37 AM
finance.yahoo.com logoVor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences
finance.yahoo.com - May 25 at 8:03 PM
finance.yahoo.com logoHow Many Vor Biopharma Inc. (NASDAQ:VOR) Shares Do Institutions Own?
finance.yahoo.com - May 7 at 8:23 PM
finance.yahoo.com logoVor Reports First Quarter 2021 Financial Results and Provides Company Update
finance.yahoo.com - May 6 at 4:43 PM
finance.yahoo.com logoVor To Present on VOR33 Manufacturing Scale-Up and Off-Target Editing at ASGCT
finance.yahoo.com - April 28 at 10:05 AM
reuters.com logoVor Biopharma Inc
reuters.com - March 30 at 10:32 PM
benzinga.com logoVor Biopharma Reports FY20 Net Loss Of $43.3M Compared To $10.8M YoY
benzinga.com - March 25 at 8:48 PM
Get Vor Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for VOR and its competitors with MarketBeat's FREE daily newsletter.

This page was last updated on 5/15/2022 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.